Patents by Inventor Bradley Andrew Murray

Bradley Andrew Murray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Reducing HLA-A in a Cell
    Publication number: 20240024478
    Abstract: Compositions and methods for reducing HLA-A protein expression in a cell comprising genetically modifying HLA-A for use e.g., in adoptive cell transfer therapies.
    Type: Application
    Filed: June 22, 2023
    Publication date: January 25, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Surbhi Goel, Yong Zhang, Reynald Michael Lescarbeau, Bradley Andrew Murray, Srijani Sridhar
  • METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY
    Publication number: 20230348852
    Abstract: The present invention provides ocular cells, genetically modified by a CRISPR system targeting the expression of B2M for ocular cell therapy. The invention further provides methods of generating an expanded population of genetically modified ocular cells, for example limbal stem cells (LSCs) or corneal endothelial cells (CECs), wherein the cells are expanded involving the use of a LATS inhibitor and the expression of B2M in the cells has been reduced or eliminated. The present invention also provides cell populations, preparations, uses and methods of therapy comprising said cells.
    Type: Application
    Filed: April 26, 2021
    Publication date: November 2, 2023
    Inventors: Frada BERENSHTEYN, Bo HAN, Xueshi HAO, Jessica HEYDER, Timothy Z. HOFFMAN, Qihui JIN, Arnaud LACOSTE, Jun LIU, Yahu LIU, Tingting MO, Bradley Andrew MURRAY, Daniel Joseph O’CONNELL, Jianfeng PAN, Yun Feng XIE, Shanshan YAN, Yefen ZOU
  • Polynucleotides, Compositions, and Methods for Polypeptide Expression
    Publication number: 20230012687
    Abstract: Compositions and methods for gene editing. In some embodiments, a polynucleotide encoding Cas9 is provided that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 19, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Bradley Andrew Murray, Christian Dombrowski, Seth C. Alexander
  • Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene Editing
    Publication number: 20210222173
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the LDHA gene are provided. Compositions and methods for treating subjects having hyperoxaluria are provided.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 22, 2021
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Zachary William Dymek, Shobu Odate, Anette Huebner, Srijani Sridhar, Bradley Andrew Murray, Walter Strapps
  • Compositions and Methods for Hydroxyacid Oxidase 1 (HAO1) Gene Editing for Treating Primary Hyperoxaluria Type 1 (PH1)
    Publication number: 20210163943
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the HAO1 gene are provided. Compositions and methods for treating subjects having primary hyperoxaluria type 1 (PH1), are provided.
    Type: Application
    Filed: January 29, 2021
    Publication date: June 3, 2021
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Zachary William Dymek, Shobu Odate, Bradley Andrew Murray, Reynald Michael Lescarbeau, Anette Huebner, Walter Strapps, Sarah Beth Hesse
  • METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY
    Publication number: 20200131474
    Abstract: The present invention provides ocular cells, genetically modified by a CRISPR system targeting the expression of B2M for ocular cell therapy. The invention further provides methods of generating an expanded population of genetically modified ocular cells, for example limbal stem cells (LSCs) or corneal endothelial cells (CECs), wherein the cells are expanded involving the use of a LATS inhibitor and the expression of B2M in the cells has been reduced or eliminated. The present invention also provides a cell populations, preparations, uses and methods of therapy comprising said cells.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 30, 2020
    Inventors: Frada BERENSHTEYN, Bo HAN, Xueshi HAO, Jessica HEYDER, Timothy Z. HOFFMAN, Qihui JIN, Arnaud LACOSTE, Jun LIU, Yahu LIU, Tingting MO, Bradley Andrew MURRAY, Daniel Joseph O'CONNELL, Jianfeng PAN, Yun Feng XIE, Shanshan YAN, Yefen ZOU
  • Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four
    Publication number: 20190142972
    Abstract: This application relates to compositions and methods for excising trinucleotide repeats (TNRs) contained within intron 3 of TCF4, such as is seen in subjects having Fuchs endothelial corneal dystrophy (FECD), PSC, and Schizophrenia. Compositions comprising guide sequences targeting the alpha 2 subunit of collagen VIII are also disclosed for treatment of mutations therein that may contribute to FECD.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 16, 2019
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Sean Michael Burns, Bradley Andrew Murray, Sarah Beth Hesse